TD Securities Boosts Bausch Health Companies (BHC) Price Target to $28.00

Bausch Health Companies (NYSE:BHC) had its price target raised by analysts at TD Securities from $24.00 to $28.00 in a research report issued on Wednesday. The firm currently has a “hold” rating on the stock. TD Securities’ price objective indicates a potential upside of 3.70% from the company’s current price.

A number of other research analysts also recently commented on the company. Royal Bank of Canada set a $31.00 price objective on Bausch Health Companies and gave the company a “hold” rating in a report on Wednesday. ValuEngine upgraded Bausch Health Companies from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright set a $25.00 price objective on Bausch Health Companies and gave the company a “hold” rating in a report on Monday, October 8th. JPMorgan Chase & Co. increased their price objective on Bausch Health Companies to $18.00 and gave the company an “underweight” rating in a report on Wednesday, August 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price objective on shares of Bausch Health Companies in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $27.55.

BHC stock traded up $0.28 during mid-day trading on Wednesday, reaching $27.00. The company had a trading volume of 212,109 shares, compared to its average volume of 4,425,310. The company has a debt-to-equity ratio of 6.99, a current ratio of 1.14 and a quick ratio of 0.89. The firm has a market capitalization of $8.45 billion, a P/E ratio of 7.03, a P/E/G ratio of 0.35 and a beta of -0.28. Bausch Health Companies has a fifty-two week low of $13.62 and a fifty-two week high of $28.45.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.31. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.09 billion. Bausch Health Companies had a positive return on equity of 27.83% and a negative net margin of 20.60%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. On average, analysts expect that Bausch Health Companies will post 3.46 EPS for the current year.

In other Bausch Health Companies news, EVP Christina Ackermann sold 19,946 shares of the stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total transaction of $498,251.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Paul Herendeen acquired 10,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were bought at an average cost of $22.61 per share, with a total value of $226,100.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 165,000 shares of company stock worth $3,890,700 in the last 90 days. 11.54% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Andra AP fonden acquired a new stake in Bausch Health Companies during the 3rd quarter worth approximately $7,039,000. Marshall Wace LLP acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $2,974,000. NEXT Financial Group Inc acquired a new stake in shares of Bausch Health Companies in the 3rd quarter valued at approximately $101,000. Point View Wealth Management Inc. acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $1,132,000. Finally, Private Management Group Inc. acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $28,474,000. 42.90% of the stock is owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Article: Penny Stocks, What You Need To Know

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply